Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Zimmer Biomet Rides On Product Launches Despite Pricing Woes

Published 01/21/2020, 10:05 PM
Updated 07/09/2023, 06:31 AM

On Jan 21, we issued an updated research report on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) . The company continues to witness strength in the Asia Pacific (APAC), Europe, the Middle East and Africa (EMEA) regions. However, pricing persists to be a major concern for this Zacks Rank #3 (Hold) stock.

Shares of this leading musculoskeletal healthcare company have outperformed its industry over the past six months. The stock has rallied 21.6% compared with the 3.7% rise of the industry.

In terms of product launch, the unveilings of ROSA robotics Knee, myMobility digital health platform (developed in partnership with Apple (NASDAQ:AAPL)), the Walter mini robotic platform and the Signature ONE Planner for upper extremities are among major achievements by Zimmer Biomet in recent times.

The company is also performing well in its priority areas like quality remediation, supply recovery efforts and product introductions. With respect to quality remediation, the company made a good progress in the third quarter. It is currently on track to complete its detailed remediation plan on the Warsaw North campus by this year-end.

Of late, Zimmer Biomet is seen to solidify its foothold in the emerging markets offering long-term opportunities. The company’s strategic investments in these zones over the last several quarters to improve its operational and sales performance are yielding results. The company expects consistent growth in the APAC and EMEA markets this year.

It should benefit from favorable long-term trends, driven by obesity, wear and tear of joints from more active lifestyles, uptick in the emerging markets, new material technologies, advancements in the surgical techniques and proven clinical benefits of joint replacement procedures.

However, in the last reported quarter, the company’s top-line growth was partially offset by an unrelenting pricing pressure, mostly in the operating segments of Americas and Europe. We are further worried about the pricing scenario as it will be affected by cost-containment efforts of governmental healthcare, local hospitals and health systems. In the third quarter, pricing pressure was a negative 2.9%, in line with the company's estimates.

Moreover, escalating costs and expenses are eroding the company’s adjusted operating margin. Adverse currency movements are a lingering downside as well.

Key Picks

Some better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , Hill-Rom Holdings, Inc (NYSE:HRC) and Medtronic plc (NYSE:MDT) .

Haemonetics currently has a Zacks Rank #1 (Strong Buy) and a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Hill-Rom’s long-term earnings growth rate is estimated at 11.7%. The company currently carries a Zacks Rank #2 (Buy).

Medtronic’s long-term earnings growth rate is expected at 7.4%. It is currently Zacks #2 Ranked.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>



Haemonetics Corporation (HAE): Free Stock Analysis Report

Hill-Rom Holdings, Inc. (HRC): Free Stock Analysis Report

Medtronic PLC (MDT): Free Stock Analysis Report

Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.